Close

Rigel Pharmaceuticals (RIGL) COVID-19 Treatment Could Be Potential Catalyst - BMO

September 17, 2020 10:04 AM EDT Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $8.00 price target on Rigel Pharmaceuticals (NASDAQ: RIGL) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login